Given that Tau accumulates approximately 10 years earlier than Aβ, and abnormal phosphorylated Tau (p‐Tau) on microtubules increases Aβ production,3 treatments targeting Tau are gradually becoming the focus for AD. Here, MAPT is linked to Alzheimer disease.